Survival time and relapse in dogs with meningoencephalomyelitis of unknown origin treated with prednisolone and ciclosporin: a retrospective study

2020 ◽  
Vol 98 (10) ◽  
pp. 491-498
Author(s):  
SL Brady ◽  
AP Woodward ◽  
MAR le Chevoir
Keyword(s):  
Retrospective Study ◽  
Survival Time ◽  
Unknown Origin ◽  
Ciclosporin A

Fever of unknown origin in the elderly: nine years experience in China

2008 ◽  
Vol 38 (4) ◽  
pp. 221-222 ◽  
Author(s):  
Minghua Zheng ◽  
Hailong Lin ◽  
Sheng Luo ◽  
Lihua Xu ◽  
Yanjun Zeng ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Connective Tissue ◽  
Connective Tissue Disease ◽  
Older Patients ◽  
Fever Of Unknown Origin ◽  
Unknown Origin ◽  
The Elderly ◽  
Medical College ◽  
Frequent Type ◽  
Wenzhou Medical College

This is a retrospective study of older patients admitted to the First and Second Affiliated Hospitals of Wenzhou Medical College, China, with a diagnosis of fever of unknown origin. The study took place from January 1998 to December 2006 among 102 patients who fulfilled the criteria. Infections were responsible for 50 cases (49.1%), followed by no diagnosis in 27 (26.5%), miscellaneous in nine (8.8%), neoplasms in eight (7.8%) and connective tissue disease in another eight (7.8%). Mycobacterium TB was the most frequent type of infection diagnosed.

scholarly journals Can Cytosine Arabinoside With Prednisolone Treatment for Canine Meningoencephalitis of Unknown Origin Increase Survival Time Compared to Prednisolone Treatment Alone?

2018 ◽  
Vol 3 (3) ◽  
Author(s):  
Christopher Stefan Francis Kozlowski Hoey ◽  
Christina Maunder
Keyword(s):  
Open Access ◽  
Combination Therapy ◽  
Survival Time ◽  
Median Survival ◽  
Cytosine Arabinoside ◽  
Median Survival Time ◽  
Unknown Origin ◽  
Bottom Line ◽  
Prednisolone Treatment ◽  
Increase Survival Time

<strong>PICO question</strong><br /><p>In treatment of canine patients with meningoencephalitis of unknown origin (MUO), is combination therapy of cytosine arabinoside (CA) with prednisolone more effective than prednisolone as a sole therapy at increasing survival time?</p><strong>Clinical bottom line</strong><br /><p>Based on current available evidence, cytosine arabinoside with prednisolone has greater median survival time than prednisolone as a sole therapy in dogs with meningoencephalitis of unknown origin. The evidence to support this is very weak, as there are currently a low number of published papers with a relatively small number of cases reported in these studies evaluating cytosine arabinoside with prednisolone or prednisolone as a sole therapy for treatment of meningoencephalitis of unknown origin.</p><p> </p><img src="https://www.veterinaryevidence.org/rcvskmod/icons/oa-icon.jpg" alt="Open Access" /> <img src="https://www.veterinaryevidence.org/rcvskmod/icons/pr-icon.jpg" alt="Peer Reviewed" />

scholarly journals A Retrospective Study of the Clinical Phenotype and Predictors of Survival in non-Caucasian Hispanic Patients with Amyotrophic Lateral Sclerosis.

2019 ◽  
Author(s):  
Claudia Marisol Sánchez-Martínez ◽  
José Alberto Choreño-Parra ◽  
Lilia Nuñez-Orozco ◽  
Noel Isaías Placencia-Álvarez ◽  
Laura Marcela Alvis-Cataño ◽  
...  
Keyword(s):  
Overall Survival ◽  
Amyotrophic Lateral Sclerosis ◽  
Prognostic Factors ◽  
Retrospective Study ◽  
Survival Time ◽  
Clinical Characteristics ◽  
Clinical Phenotype ◽  
Age At Onset ◽  
Als Patients ◽  
Lateral Sclerosis

Abstract Background. Little is known about the clinical phenotype of amyotrophic lateral sclerosis (ALS) in non-Caucasian populations. Here, we aimed to describe the clinical characteristics, prognostic factors and survival of Mexican patients with ALS. Methods. We conducted a retrospective study by reviewing the medical records of patients with ALS that attended and were regularly followed at a third level hospital in Mexico City from 2000 to 2015. We calculated absolute and relative frequencies of the clinical characteristics from all the participants. We also estimated correlation coefficients between clinical features and overall survival. Additionally, survival rates were compared for all participants grouped according to different clinical features using the Kaplan-Meier method and the log-rank test. Results. We enrolled 45 ALS patients, 53.33% had spinal-onset ALS and 46.66% presented bulbar ALS. The male/female ratio was 0.8. The mean age at onset of symptoms was 58.11 years. Mean survival time from onset was 64.73 ± 34.83 months. Cumulative survival rate after 5 years of disease onset was 44.44%. Age at onset and age at diagnosis inversely correlated with overall survival time. Also, we found that bulbar-onset, short diagnostic delay, percutaneous endoscopic gastrostomy, mechanical ventilation, and lower total cholesterol serum levels were associated with short survival. Conclusions. The clinical characteristics of Mexican ALS patients differ from the disease phenotype observed in Caucasians. Nonetheless, the predictive value of certain well-recognized prognostic factors remains consistent in our population. The current study provides relevant information for a better understanding of prognostic factors in ALS patients from Mexico and other Latin American countries.

scholarly journals End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study

BMJ Open ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. e026309 ◽  
Author(s):  
Zhong Li ◽  
Zijing Pan ◽  
Liang Zhang ◽  
Ruibo He ◽  
Shan Jiang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Survival Time ◽  
Cancer Patients ◽  
Healthcare Utilisation ◽  
Population Based ◽  
Basic Medical Insurance ◽  
Inpatient Hospitalisation ◽  
Ed Visits ◽  
Aggressive Care ◽  
Basic Medical

ObjectiveThis study aimed to define the end-of-life (EOL) healthcare utilisation and its cost and determinants for cancer patients and to proactively inform related strategies in mainland China.DesignA population-based retrospective study.Setting and participantsData from 894 cancer patients were collected in urban Yichang, China from 01 July 2015 to 30 June 2017.Outcome measuresEmergency department (ED) visits, outpatient and inpatient hospitalisation services, intensive care unit (ICU) admission and total costs were used as the main outcomes.ResultsIn this study, 66.8% of the 894 patients were male, and the average age was 60.4 years. Among these patients, 37.6% died at home, and patients had an average of 4.86 outpatient services, 2.23 inpatient hospitalisation services and 1.44 ED visits. Additionally, 5.9% of these patients visited the ICU at least once. During the EOL periods, the costs in the last 6 months, 3 months, 1 month and 1 week were US$18 234, US$13 043, US$6349 and US$2085, respectively. The cost increased dramatically as death approached. The estimation results of generalised linear regression models showed that aggressive care substantially affected expenditure. Patients with Urban Employee Basic Medical Insurance spent more than those with Urban Resident-based Basic Medical Insurance or the New Rural Cooperative Medical Scheme. The place of death and the survival time are also risk factors for increased EOL cost.ConclusionThe findings suggested that the EOL cost for cancer patients is associated with aggressive care, insurance type and survival time. Timing palliative care is urgently needed to address ineffective and irrational healthcare utilisation and to reduce costs.Ethics and disseminationThis study was approved by the Ethics Committee of the Tongji Medical College, Huazhong University of Science and Technology (IORG No.: IORG0003571). All the data used in this study were de-identified.

scholarly journals A Retrospective Study of Hospitalized Patients with Fever of Unknown Origin (FUO) during Six Years

1990 ◽  
Vol 64 (3) ◽  
pp. 335-341 ◽  
Author(s):  
Hiroshi FUKUHARA ◽  
Kazunori TAMAKI ◽  
Hiroaki NAKAMURA ◽  
Hiroshi KANESIMA ◽  
Yuei IRABU ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Fever Of Unknown Origin ◽  
Unknown Origin ◽  
Hospitalized Patients

A Retrospective Study on Canine Epilepsy: Etiological Distribution, Therapeutic Outcome, and Survival Time

2019 ◽  
Vol 36 (3) ◽  
pp. 150-154
Author(s):  
Seo-Yeon Park ◽  
Yoonsoo Jeong ◽  
Taesik Yun ◽  
Dong-In Jung ◽  
Dong-Woo Chang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Survival Time ◽  
Therapeutic Outcome

scholarly journals Diagnostic workup for fever of unknown origin: a multicenter collaborative retrospective study

BMJ Open ◽  
2013 ◽  
Vol 3 (12) ◽  
pp. e003971 ◽  
Author(s):  
Toshio Naito ◽  
Masafumi Mizooka ◽  
Fujiko Mitsumoto ◽  
Kenji Kanazawa ◽  
Keito Torikai ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Fever Of Unknown Origin ◽  
Unknown Origin ◽  
Diagnostic Workup

Radiation therapy in the treatment of canine and feline thymomas: a retrospective study (1985-1999)

2001 ◽  
Vol 37 (5) ◽  
pp. 489-496 ◽  
Author(s):  
AN Smith ◽  
JC Wright ◽  
Brawner WRJr ◽  
SM LaRue ◽  
L Fineman ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Retrospective Study ◽  
Survival Time ◽  
Median Survival ◽  
Stable Disease ◽  
Tumor Size ◽  
Median Survival Time ◽  
Overall Response Rate ◽  
Response Rate ◽  
Clinical Signs

A retrospective study was performed of 17 dogs and seven cats with various stages of thymoma treated with radiation alone or as an adjunctive therapy. Analysis revealed an overall response rate of 75% (15/20 evaluable cases). Partial (i.e., &gt;50% reduction in tumor size) and complete (i.e., no detectable tumor) responses were included. Complete responses were rare (4/20). Three of five animals with stable disease (i.e., &lt;50% change in tumor size) had improvements in clinical signs, despite lack of measurable response. A median survival time of 248 days (range, 93 to 1,657+ days) was achieved in dogs, and a median survival time of 720 days (range, 485 to 1,825+ days) was achieved in cats. Radiation therapy appears to be useful in the management of invasive thymomas in dogs and cats.

scholarly journals Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational Study

2019 ◽  
Vol 220 (2) ◽  
pp. 195-202 ◽  
Author(s):  
Romy Kerber ◽  
Eva Lorenz ◽  
Sophie Duraffour ◽  
Daouda Sissoko ◽  
Martin Rudolf ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Survival Time ◽  
Ebola Virus ◽  
Virus Disease ◽  
Univariate Analysis ◽  
Case Fatality ◽  
Blood Chemistry ◽  
Ebola Virus Disease ◽  
Treatment Center ◽  
Compassionate Use

Abstract Background In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. The cycle threshold (Ct) of an Ebola virus–specific reverse transcription–polymerase chain reaction assay and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to patients with EVD on a compassionate-use basis. Methods To reduce biases in the raw field data, we carefully selected 163 of 286 patients with EVD for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry findings, favipiravir treatment, and outcome. Results The case-fatality rate in favipiravir-treated patients was lower than in untreated patients (42.5% [31 of 73] vs 57.8% [52 of 90]; P = .053 by univariate analysis). In multivariate regression analysis, a higher Ct and a younger age were associated with survival (P < .001), while favipiravir treatment showed no statistically significant effect (P = .11). However, Kaplan-Meier analysis indicated a longer survival time in the favipiravir-treated group (P = .015). The study also showed characteristic changes in blood chemistry findings in patients who died, compared with survivors. Conclusions Consistent with the JIKI trial, this retrospective study revealed a trend toward improved survival in favipiravir- treated patients; however, the effect of treatment was not statistically significant, except for its influence on survival time.

Sign in / Sign up

Export Citation Format

Share Document